Terms: = Sarcomas AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Treatment
64 results:
1. The role of systemic therapy in advanced skull base chordomas: overview of the current state and the MD Anderson protocol.
Banu MA; Raza SM; Amini M; Seaman S; Rubino F; Snyder R; Patel S; DeMonte F; Conley AP
Neurosurg Focus; 2024 May; 56(5):E15. PubMed ID: 38691867
[TBL] [Abstract] [Full Text] [Related]
2. treatment of Thoracic SMARCA4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go.
Longo V; Catino A; Montrone M; Montagna ES; Pesola F; Marech I; Pizzutilo P; Nardone A; Perrone A; Gesualdo M; Galetta D
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542211
[TBL] [Abstract] [Full Text] [Related]
3. Pharmacology and pharmacokinetics of tazemetostat.
Orleni M; Beumer JH
Cancer Chemother Pharmacol; 2024 May; 93(5):509-517. PubMed ID: 38520556
[TBL] [Abstract] [Full Text] [Related]
4. The efficacy and safety of vincristine, irinotecan and anlotinib in Epithelioid Sarcoma.
Xie L; Sun X; Xu J; Liang X; Liu K; Sun K; Yang R; Tang X; Guo W
BMC Cancer; 2024 Feb; 24(1):172. PubMed ID: 38310286
[TBL] [Abstract] [Full Text] [Related]
5. A miniaturized mode-of-action profiling platform enables high throughput characterization of the molecular and cellular dynamics of ezh2 inhibition.
Falkenstern L; Georgi V; Bunse S; Badock V; Husemann M; Roehn U; Stellfeld T; Fitzgerald M; Ferrara S; Stöckigt D; Stresemann C; Hartung IV; Fernández-Montalván A
Sci Rep; 2024 Jan; 14(1):1739. PubMed ID: 38242973
[TBL] [Abstract] [Full Text] [Related]
6. Pharmacological ezh2 inhibition combined with retinoic acid treatment promotes differentiation and apoptosis in rhabdomyosarcoma cells.
O'Brien E; Tse C; Tracy I; Reddin I; Selfe J; Gibson J; Tapper W; Pengelly RJ; Gao J; Aladowicz E; Petts G; Thway K; Popov S; Kelsey A; Underwood TJ; Shipley J; Walters ZS
Clin Epigenetics; 2023 Oct; 15(1):167. PubMed ID: 37858275
[TBL] [Abstract] [Full Text] [Related]
7. Transcriptomic subtyping of malignant peripheral nerve sheath tumours highlights immune signatures, genomic profiles, patient survival and therapeutic targets.
Høland M; Berg KCG; Eilertsen IA; Bjerkehagen B; Kolberg M; Boye K; Lingjærde OC; Guren TK; Mandahl N; van den Berg E; Palmerini E; Smeland S; Picci P; Mertens F; Sveen A; Lothe RA
EBioMedicine; 2023 Nov; 97():104829. PubMed ID: 37837931
[TBL] [Abstract] [Full Text] [Related]
8. Delayed diagnosis of pediatric intra-articular epithelioid sarcoma: a case report and literature review.
Zhang R; Liu J; Liu L; Lin Y; Zhang Q
BMC Pediatr; 2023 Sep; 23(1):488. PubMed ID: 37752442
[TBL] [Abstract] [Full Text] [Related]
9. Pharmacotherapeutic strategies for epithelioid sarcoma: are we any closer to a non-surgical cure?
Meissner M; Napolitano A; Thway K; Huang P; Jones RL
Expert Opin Pharmacother; 2023; 24(12):1395-1401. PubMed ID: 37326105
[TBL] [Abstract] [Full Text] [Related]
10. Tazemetostat for tumors harboring SMARCB1/SMARCA4 or ezh2 alterations: results from NCI-COG pediatric MATCH APEC1621C.
Chi SN; Yi JS; Williams PM; Roy-Chowdhuri S; Patton DR; Coffey BD; Reid JM; Piao J; Saguilig L; Alonzo TA; Berg SL; Ramirez NC; Jaju A; Mhlanga JC; Fox E; Hawkins DS; Mooney MM; Takebe N; Tricoli JV; Janeway KA; Seibel NL; Parsons DW
J Natl Cancer Inst; 2023 Nov; 115(11):1355-1363. PubMed ID: 37228094
[TBL] [Abstract] [Full Text] [Related]
11. Dysregulation of iron homeostasis by TfR-1 renders ezh2 wild type diffuse large B-cell lymphoma resistance to ezh2 inhibition.
Yu L; Wang YF; Xiao J; Shen QQ; Chi SS; Gao YL; Lin DZ; Ding J; Fang YF; Chen Y
Acta Pharmacol Sin; 2023 Oct; 44(10):2113-2124. PubMed ID: 37225847
[TBL] [Abstract] [Full Text] [Related]
12. New targeted treatments for advanced sarcomas.
Li CC; Chen TW
Curr Opin Oncol; 2023 Jul; 35(4):309-314. PubMed ID: 37222206
[TBL] [Abstract] [Full Text] [Related]
13. Capsaicin Reduces Cancer Stemness and Inhibits Metastasis by Downregulating
Chen ZY; Huang HH; Li QC; Zhan FB; Wang LB; He T; Yang CH; Wang Y; Zhang Y; Quan ZX
Am J Chin Med; 2023; 51(4):1041-1066. PubMed ID: 37120706
[TBL] [Abstract] [Full Text] [Related]
14. ezh2/hSULF1 axis mediates receptor tyrosine kinase signaling to shape cartilage tumor progression.
Lin ZS; Chung CC; Liu YC; Chang CH; Liu HC; Liang YY; Huang TL; Chen TM; Lee CH; Tang CH; Hung MC; Chen YH
Elife; 2023 Jan; 12():. PubMed ID: 36622753
[TBL] [Abstract] [Full Text] [Related]
15. Alpha Ketoglutarate Downregulates the Neutral Endopeptidase and Enhances the Growth Inhibitory Activity of Thiorphan in Highly Aggressive Osteosarcoma Cells.
Mizerska-Kowalska M; Sławińska-Brych A; Niedziela E; Brodovskiy V; Zdzisińska B
Molecules; 2022 Dec; 28(1):. PubMed ID: 36615293
[TBL] [Abstract] [Full Text] [Related]
16. Head-and-neck dermatofibrosarcoma protuberans: Survival analysis and Clinically relevant immunohistochemical indicators.
Dai Z; He Y; Zhang X; Tian Z; Zhu G; Ren Z; Ye L; Liu Z; Ma C; Cao W; Ji T
Oral Dis; 2024 Apr; 30(3):1040-1051. PubMed ID: 36597156
[TBL] [Abstract] [Full Text] [Related]
17. Identification and treatment of SMARCA4 Deficient Poorly Differentiated Gastric Carcinoma.
Bhat V; Koneru M; Knapp K; Joneja U; Morrison J; Hong YK
Am Surg; 2023 Nov; 89(11):4987-4989. PubMed ID: 36533880
[TBL] [Abstract] [Full Text] [Related]
18. ezh2 promotes the progression of osteosarcoma through the activation of the AKT/GSK3β pathway.
Wan D; Han X; Zhang C; Zhang Y; Ma Y; Wang G
Clin Exp Pharmacol Physiol; 2022 Nov; 49(11):1179-1186. PubMed ID: 35818168
[TBL] [Abstract] [Full Text] [Related]
19. Chemical biology and pharmacology of histone lysine methylation inhibitors.
Barghout SH; Machado RAC; Barsyte-Lovejoy D
Biochim Biophys Acta Gene Regul Mech; 2022 Aug; 1865(6):194840. PubMed ID: 35753676
[TBL] [Abstract] [Full Text] [Related]
20. NSD1 mediates antagonism between SWI/SNF and polycomb complexes and is required for transcriptional activation upon ezh2 inhibition.
Drosos Y; Myers JA; Xu B; Mathias KM; Beane EC; Radko-Juettner S; Mobley RJ; Larsen ME; Piccioni F; Ma X; Low J; Hansen BS; Peters ST; Bhanu NV; Dhanda SK; Chen T; Upadhyaya SA; Pruett-Miller SM; Root DE; Garcia BA; Partridge JF; Roberts CWM
Mol Cell; 2022 Jul; 82(13):2472-2489.e8. PubMed ID: 35537449
[TBL] [Abstract] [Full Text] [Related]
[Next]
